Learn what AI-designed small molecule drugs are and how AI and machine learning are revolutionizing oral drug discovery, from de novo molecular design and multi-parameter optimization to faster, safer clinical candidates.
Explore how CRISPR-based gene editing is evolving from lab tool to real drug candidate. Learn what makes CRISPR medicines different from traditional therapies, key clinical-stage modalities, and the safety, delivery, and ethical challenges ahead.
Discover how AI-powered pharmacovigilance is transforming drug safety from static databases to intelligent, real-time safety monitoring. Learn how NLP, machine learning, and predictive risk modeling enable earlier signal detection, better risk stratification, and smarter regulatory decision-making.
Learn how tirzepatide, a dual GIP/GLP‑1 receptor agonist, differs from traditional GLP‑1 drugs like semaglutide. Discover its mechanism, once‑weekly dosing, and impact on blood sugar, weight loss, and cardiometabolic risk in type 2 diabetes and obesity.
Discover how AI-driven pharmacovigilance is revolutionizing drug safety in 2025. Learn how machine learning, NLP, and predictive risk models turn static safety databases into continuous safety intelligence for faster, more accurate signal detection.
Discover why small molecule antivirals are entering a new golden age. Learn how next-generation oral antivirals targeting viral polymerases and proteases are reshaping treatment for COVID-19, RSV, and emerging viral threats.
Learn what deucravacitinib is, how its selective TYK2 inhibition differs from traditional JAK inhibitors, and why it’s becoming a leading oral treatment option for moderate-to-severe plaque psoriasis based on Phase 3 POETYK PSO clinical trial data.
Discover how AI and machine learning are reshaping pharmacovigilance by automating case intake, enhancing signal detection, and enabling real-time safety monitoring across EHRs, claims, literature, and social media—without replacing human expertise.
Learn how tirzepatide’s dual GIP/GLP‑1 “twincretin” mechanism delivers deeper HbA1c reductions, significant weight loss, and broader cardiometabolic benefits. Explore the peptide engineering behind this next‑generation incretin therapy for type 2 diabetes and obesity.
Learn how next‑generation small molecule PROTACs go beyond inhibition to eliminate disease‑driving proteins. Explore their mechanism, improved selectivity, oral bioavailability, and ability to target previously “undruggable” proteins using advanced ternary complex design and diversified E3 ligases.